IsoRay, Inc. (ISR) VP Buys $27,500.00 in Stock
IsoRay, Inc. (NYSEAMERICAN:ISR) VP Michael Krachon bought 55,000 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The shares were acquired at an average cost of $0.50 per share, with a total value of $27,500.00. Following the completion of the purchase, the vice president now owns 19,609 shares of the company’s stock, valued at $9,804.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
IsoRay, Inc. (NYSEAMERICAN ISR) traded up $0.02 during midday trading on Tuesday, reaching $0.48. 113,800 shares of the company’s stock traded hands, compared to its average volume of 113,058. IsoRay, Inc. has a 52 week low of $0.38 and a 52 week high of $0.70.
IsoRay (NYSEAMERICAN:ISR) last released its quarterly earnings data on Tuesday, November 14th. The healthcare company reported ($0.03) EPS for the quarter. The business had revenue of $1.21 million for the quarter. IsoRay had a negative return on equity of 65.23% and a negative net margin of 135.40%.
Separately, Maxim Group set a $3.00 price target on shares of IsoRay and gave the stock a “buy” rating in a research note on Wednesday, November 15th.
IsoRay Company Profile
IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.
Receive News & Ratings for IsoRay Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay Inc. and related companies with MarketBeat.com's FREE daily email newsletter.